Literature DB >> 31284746

TGF-β1-p53 cooperativity regulates a profibrotic genomic program in the kidney: molecular mechanisms and clinical implications.

Craig E Higgins1, Jiaqi Tang1, Badar M Mian2,3, Stephen P Higgins1, Cody C Gifford1, David J Conti4, Kirstan K Meldrum5, Rohan Samarakoon1, Paul J Higgins1,2,3.   

Abstract

Chronic kidney disease affects >15% of the U.S. population and >850 million individuals worldwide. Fibrosis is the common outcome of many chronic renal disorders and, although the etiology varies (i.e., diabetes, hypertension, ischemia, acute injury, and urologic obstructive disorders), persistently elevated renal TGF-β1 levels result in the relentless progression of fibrotic disease. TGF-β1 orchestrates the multifaceted program of renal fibrogenesis involving proximal tubular dysfunction, failed epithelial recovery and redifferentiation, and subsequent tubulointerstitial fibrosis, eventually leading to chronic renal disease. Recent findings implicate p53 as a cofactor in the TGF-β1-induced signaling pathway and a transcriptional coregulator of several TGF-β1 profibrotic response genes by complexing with receptor-activated SMADs, which are homologous to the small worms (SMA) and Drosophilia mothers against decapentaplegic (MAD) gene families. The cooperative p53-TGF-β1 genomic cluster includes genes involved in cell growth control and extracellular matrix remodeling [e.g., plasminogen activator inhibitor-1 (PAI-1; serine protease inhibitor, clade E, member 1), connective tissue growth factor, and collagen I]. Although the molecular basis for this codependency is unclear, many TGF-β1-responsive genes possess p53 binding motifs. p53 up-regulation and increased p53 phosphorylation; moreover, they are evident in nephrotoxin- and ischemia/reperfusion-induced injury, diabetic nephropathy, ureteral obstructive disease, and kidney allograft rejection. Pharmacologic and genetic approaches that target p53 attenuate expression of the involved genes and mitigate the fibrotic response, confirming a key role for p53 in renal disorders. This review focuses on mechanisms whereby p53 functions as a transcriptional regulator within the TGF-β1 cluster with an emphasis on the potent fibrosis-promoting PAI-1 gene.-Higgins, C. E., Tang, J., Mian, B. M., Higgins, S. P., Gifford, C. C., Conti, D. J., Meldrum, K. K., Samarakoon, R., Higgins, P. J. TGF-β1-p53 cooperativity regulates a profibrotic genomic program in the kidney: molecular mechanisms and clinical implications.

Entities:  

Keywords:  PAI-1; SMADs; fibrosis; gene expression; renal disease

Mesh:

Substances:

Year:  2019        PMID: 31284746      PMCID: PMC6766640          DOI: 10.1096/fj.201900943R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.834


  140 in total

1.  Interplay between the tumor suppressor p53 and TGF beta signaling shapes embryonic body axes in Xenopus.

Authors:  Kimiko Takebayashi-Suzuki; Jun Funami; Daisuke Tokumori; Akira Saito; Tetsuro Watabe; Kohei Miyazono; Akifumi Kanda; Atsushi Suzuki
Journal:  Development       Date:  2003-09       Impact factor: 6.868

Review 2.  The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor.

Authors:  James J Manfredi
Journal:  Genes Dev       Date:  2010-08-01       Impact factor: 11.361

3.  Acute renal failure in critically ill patients: a multinational, multicenter study.

Authors:  Shigehiko Uchino; John A Kellum; Rinaldo Bellomo; Gordon S Doig; Hiroshi Morimatsu; Stanislao Morgera; Miet Schetz; Ian Tan; Catherine Bouman; Ettiene Macedo; Noel Gibney; Ashita Tolwani; Claudio Ronco
Journal:  JAMA       Date:  2005-08-17       Impact factor: 56.272

4.  A multi-center evaluation of early acute kidney injury in critically ill trauma patients.

Authors:  Sean M Bagshaw; Carol George; R T Noel Gibney; Rinaldo Bellomo
Journal:  Ren Fail       Date:  2008       Impact factor: 2.606

Review 5.  p53 brings a new twist to the Smad signaling network.

Authors:  Azeddine Atfi; Roland Baron
Journal:  Sci Signal       Date:  2008-07-01       Impact factor: 8.192

6.  siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury.

Authors:  Bruce A Molitoris; Pierre C Dagher; Ruben M Sandoval; Silvia B Campos; Hagit Ashush; Eduard Fridman; Anat Brafman; Alexander Faerman; Simon J Atkinson; James D Thompson; Hagar Kalinski; Rami Skaliter; Shai Erlich; Elena Feinstein
Journal:  J Am Soc Nephrol       Date:  2009-05-21       Impact factor: 10.121

7.  Origin and function of myofibroblasts in kidney fibrosis.

Authors:  Valerie S LeBleu; Gangadhar Taduri; Joyce O'Connell; Yingqi Teng; Vesselina G Cooke; Craig Woda; Hikaru Sugimoto; Raghu Kalluri
Journal:  Nat Med       Date:  2013-06-30       Impact factor: 53.440

Review 8.  Convergence of p53 and TGF-beta signaling networks.

Authors:  Sirio Dupont; Luca Zacchigna; Maddalena Adorno; Sandra Soligo; Dino Volpin; Stefano Piccolo; Michelangelo Cordenonsi
Journal:  Cancer Lett       Date:  2004-09-30       Impact factor: 8.679

9.  p53 requires the stress sensor USF1 to direct appropriate cell fate decision.

Authors:  Amine Bouafia; Sébastien Corre; David Gilot; Nicolas Mouchet; Sharon Prince; Marie-Dominique Galibert
Journal:  PLoS Genet       Date:  2014-05-15       Impact factor: 5.917

10.  NUMB maintains bone mass by promoting degradation of PTEN and GLI1 via ubiquitination in osteoblasts.

Authors:  Ling Ye; Feng Lou; Fanyuan Yu; Demao Zhang; Chenglin Wang; Fanzi Wu; Xin Li; Yilin Ping; Xiao Yang; Jing Yang; Dian Chen; Bo Gao; Dingming Huang; Peng Liu
Journal:  Bone Res       Date:  2018-11-10       Impact factor: 13.567

View more
  8 in total

1.  SIRT3 Deficiency Sensitizes Angiotensin-II-Induced Renal Fibrosis.

Authors:  Xiaomeng Feng; Han Su; Xiaochen He; Jian-Xiong Chen; Heng Zeng
Journal:  Cells       Date:  2020-11-20       Impact factor: 6.600

2.  Using Network Pharmacology to Explore the Mechanism of Peach Kernel-Safflower in the Treatment of Diabetic Nephropathy.

Authors:  Jingxue Han; Xinwei Wang; Jingyi Hou; Yu Liu; Peng Liu; Tingting Zhao
Journal:  Biomed Res Int       Date:  2021-02-01       Impact factor: 3.411

Review 3.  Mitochondrial Pathophysiology on Chronic Kidney Disease.

Authors:  Patrícia C Braga; Marco G Alves; Anabela S Rodrigues; Pedro F Oliveira
Journal:  Int J Mol Sci       Date:  2022-02-04       Impact factor: 5.923

4.  ATRvD1 Attenuates Renal Tubulointerstitial Injury Induced by Albumin Overload in Sepsis-Surviving Mice.

Authors:  José Bruno N F Silva; Thayanne B B Calcia; Cyntia P Silva; Rafael F Guilherme; Fernando Almeida-Souza; Felipe S Lemos; Kátia S Calabrese; Celso Caruso-Neves; Josiane S Neves; Claudia F Benjamim
Journal:  Int J Mol Sci       Date:  2021-10-27       Impact factor: 5.923

Review 5.  Cancer-Associated Fibroblasts: Mechanisms of Tumor Progression and Novel Therapeutic Targets.

Authors:  Ralf-Peter Czekay; Dong-Joo Cheon; Rohan Samarakoon; Stacie M Kutz; Paul J Higgins
Journal:  Cancers (Basel)       Date:  2022-02-27       Impact factor: 6.639

6.  Value of urine IL-8, NGAL and KIM-1 for the early diagnosis of acute kidney injury in patients with ureteroscopic lithotripsy related urosepsis.

Authors:  Dan Tan; Liang Zhao; Wei Peng; Fang-Hao Wu; Guo-Bin Zhang; Bo Yang; Wen-Qian Huo
Journal:  Chin J Traumatol       Date:  2021-10-11

7.  Novel Synthetic Polymer-Based 3D Contraction Assay: A Versatile Preclinical Research Platform for Fibrosis.

Authors:  Jyoti Kumari; Frank A D T G Wagener; Paul H J Kouwer
Journal:  ACS Appl Mater Interfaces       Date:  2022-04-25       Impact factor: 10.383

Review 8.  The Genomic Response to TGF-β1 Dictates Failed Repair and Progression of Fibrotic Disease in the Obstructed Kidney.

Authors:  Craig E Higgins; Jiaqi Tang; Stephen P Higgins; Cody C Gifford; Badar M Mian; David M Jones; Wenzheng Zhang; Angelica Costello; David J Conti; Rohan Samarakoon; Paul J Higgins
Journal:  Front Cell Dev Biol       Date:  2021-07-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.